MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ubiquitin proteasome system(UPS)"

  • MDS Virtual Congress 2020

    Relationship between tumor and very slow Parkinson`s disease progression

    H. Mori (Kurashiki, Okayama, Japan)

    Objective: We evaluate the Parkinson`s disease patients with very slow progression. One of their clinical features are the medical history of tumor. Background: Some cancer…
  • 2018 International Congress

    Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) -mediated ubiquitination attributed to localization of Mortalin to mitochondria

    L. Wu, W. Yang, Y. Tan, J. Ding, S. Chen (Shanghai, China)

    Objective: The pathogenic mechanism of UCHL1 in PD remains unclear. In this study, we aimed to investigate the role of UCHL1 in the pathogenesis of…
  • 2018 International Congress

    A pilot study of plasma ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) as a potential blood-based biomarker in Parkinson’s disease

    A. Ng, YJ. Tan, ZH. Lu, S. Ng, E. Ng, F. Setiawan, N. Keong, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To determine plasma levels of UCH-L1 in patients with PD, and to investigate the association with both genetic (leucine-rich repeat kinase 2, LRRK2 and…
  • 2016 International Congress

    The role and underlying mechanisms of BAG3 in regulating autophagy in PC12 cells

    Y.P. Yang, Y.L. Cao, C.J. Mao, F. Wang, L.F. Hu, C.F. Liu (Suzhou, People's Republic of China)

    Objective: To detect the role of Bcl-2-associated athanogene 3 (BAG3) in regulating autophagy in PC12 cells and explore the underlying mechanisms of it. Background: Increasing…
  • 2016 International Congress

    Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

    F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

    Objective: To characterize the response of cells treated with Gamitrinib-triphenylphosphonium (G-TTP) a mitochondrial targeted inhibitor of the chaperone Hsp90. Background: Upon dissipation of the mitochondrial…
  • 2016 International Congress

    Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

    W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

    Objective: To investigate the possible disease-association and pathogenic mechanisms of heterozygous PINK1 mutations from a genetic, functional, and structural perspective. Background: It has been postulated…
  • 2016 International Congress

    Functional characterisation and the selective vulnerability of SNCA (A30P) patient-derived midbrain dopaminergic neurons to ER stress

    P.A. Barbuti, B.F.R. Santos, S. Delcambre, Y. Nonnenmacher, C.D. Obermaier, A. Hummel, K. Hiller, R. Krueger (Belvaux, Luxembourg)

    Objective: To functional characterise and phenotype the genetic Parkinson's disease (PD) patient with an A30P point mutation in SNCA using midbrain dopaminergic neurons (mDANs) vs…
  • 2016 International Congress

    Three cases of neuronal intranuclear inclusion disease (NIID)

    Y. Miyamoto, Y. Morita, K. Furuta, Y. Osaki, H. Arahata, A. Watanabe, N. Fujii, T. Iwaki, H. Furuya (Kochi, Japan)

    Objective: Here, we present three NIID cases. One of them, autopsy was performed. Background: Neuronal intranuclear inclusion disease (NIID)(OMIM 603472) is a neurodegenerative disorder characterized…
  • 2016 International Congress

    Loss of FBXO7 (PARK15) leads to disturbances in proteasomal function and models parkinsonism-like and pyramidal symptoms in mice

    S. Vingill, D. Brockelt, N. Schwedhelm-Domeyer, L. Tatenhorst, S. Goebbels, P. Lingor, K.A. Nave, J. Stegmueller (Goettingen, Germany)

    Objective: To model Parkinsonian-pyramidal syndrome (PARK15) in mice and investigate the impact of loss of F-box only protein 7 (FBXO7) in neurons on proteasomal activity.…

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23107 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley